Thu.Sep 22, 2022

Servier cuts ties with Allogene, ending complex CAR-T partnership

Bio Pharma Dive

The French drugmaker terminated a nearly decade-old deal that helped Allogene emerge as the sector's largest "off-the-shelf" cell therapy developer

Micro-robots, smart toilets, and 3D bioprinted organs: the future of healthcare

Pharmaceutical Technology

It is the year 2030. You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer.

Genome 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

GSK buys into Spero’s comeback plan

Bio Pharma Dive

The British drugmaker is investing in Spero Therapeutics and acquiring most of the rights to an oral antibiotic the FDA previously rejected, but could approve if it succeeds in a new Phase 3 trial

Trials 181

Eli Lilly's Retevmo wins FDA nod to treat all cancer types with rare RET biomarker

Fierce Pharma

Eli Lilly's Retevmo wins FDA nod to treat all cancer types with rare RET biomarker. kdunleavy. Thu, 09/22/2022 - 10:26

100
100

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

Lilly drug wins FDA clearance for gene-mutated solid tumors, regardless of type

Bio Pharma Dive

The approval is another example of so-called tissue-agnostic indications, which are based on a cancer’s genetic signature rather than where it is in the body

Merck, defending its blockbuster Januvia, prevails in high-stakes patent lawsuit against Viatris

Fierce Pharma

Merck, defending its blockbuster Januvia, prevails in high-stakes patent lawsuit against Viatris. esagonowsky. Thu, 09/22/2022 - 09:30

94

More Trending

Novartis dons 'US-first' mindset amid groupwide overhaul, layoffs and generics spinoff

Fierce Pharma

Novartis dons 'US-first' mindset amid groupwide overhaul, layoffs and generics spinoff. Thu, 09/22/2022 - 10:15

91

Novartis warns of sales hit after federal court turns back patent appeal

Bio Pharma Dive

The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya

Sales 149

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

Fierce Pharma

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on. fkansteiner. Wed, 09/21/2022 - 10:20

Sales 87

Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’

Bio Pharma Dive

The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

NICE says yes to BeiGene’s Brukinsa after Scottish nay

Pharma Phorum

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL).

Drugs 83

Fennec wins approval of first drug for chemotherapy-induced hearing loss in children

Bio Pharma Dive

The drug, Pedmark, has been in development for more than two decades and was previously rejected twice by U.S. regulators

Biden admin says Supreme Court should reject Amgen's petition to take up Repatha patent case

Fierce Pharma

Biden admin says Supreme Court should reject Amgen's petition to take up Repatha patent case. zbecker. Thu, 09/22/2022 - 13:19

82

Reconfiguring COVID and influenza vaccines for long-term effectiveness

Pharma Phorum

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect.

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Scientists Develop Test for Parkinson’s Based on Woman’s Ability to Smell the Disease

XTalks

Scientists at the University of Manchester in the UK have developed a test for Parkinson’s disease using information from a woman’s unique sense of smell that can detect the condition.

No Walk in the Park: JAMA Editorial Calls for More Park Prosecutions; We Disagree

The FDA Law Blog

By Jeffrey N.

4 Trends to Watch on Native Advertising

Pharma Marketing Network

Online users are constantly exposed to ads, especially since the beginning of the COVID-19 pandemic. Since traditional advertising can be intrusive and lack targeting and customization, it is becoming less popular among advertisers and marketers.

Envirotainer’s Air Freight Container Awarded Multiple Swedish Patents

Pharmaceutical Commerce

Include frost protection, air flow to protect pharmaceuticals.

A Comprehensive Guide to Help You Understand Toenail Fungus

Olympian Clinical Research

It is estimated that about 14% of the population will experience onychomycosis, more commonly known as toenail fungus, at some point in their lives. Toenail fungus may affect people of all ages, but it is more common in adults over 60.

Film dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for film dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Film dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions. Infographic

Drugs 82

'The Top Line': How some Big Pharmas are bolstering their environmental sustainability efforts, the most expensive drug and more

Fierce Pharma

The Top Line': How some Big Pharmas are bolstering their environmental sustainability efforts, the most expensive drug and more. tcarey. Thu, 09/22/2022 - 13:57

Drugs 56

GSK and Spero enter licence deal for cUTI antibiotic

Pharmaceutical Technology

GSK has signed an exclusive licence agreement with Spero Therapeutics for the latter’s tebipenem pivoxil hydrobromide (tebipenem HBr) treatment for complicated urinary tract infections (cUTI).

CRO Parexel focuses on RWE strategy to put patients first

Outsourcing Pharma

Parexel is utilizing a real-world evidence (RWE) strategy to understand patient populations, shorten timelines, and get treatments into patientâs hands. Clinical Development

Avrobio receives FDA rare pediatric disease status for cystinosis therapy

Pharmaceutical Technology

Avrobio has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, AVR-RD-04, designed to treat cystinosis.

Spevigo Becomes First Treatment Option for Generalized Pustular Psoriasis Flares

XTalks

Psoriasis is a common, chronic skin condition that results in rashes and itchy scaly patches. The rashes can be painful, distracting and even interfere with sleep. A rare variation of psoriasis is generalized pustular psoriasis (GPP) , a neutrophilic skin disease.

Gene 52

Cell-based therapies set to become major players in the osteoarthritis market

Pharmaceutical Technology

Osteoarthritis (OA) is a slowly progressive joint disease that is a major cause of disability and pain among the elderly, second only to cardiovascular disease.

Deep Dive: Communications & Commercialisation 2022

Pharma Phorum

There is little doubt that the arrival of COVID-19 changed the game for communication and commercialisation efforts for pharmaceutical companies around the world.

CRO Paraxel focuses on RWE strategy to put patients first

Outsourcing Pharma

Paraxel is utilizing a real-world evidence (RWE) strategy to understand patient populations, shorten timelines, and get treatments into patientâs hands. Clinical Development

New Biotechnology and Biomanufacturing Executive Order + Steakholder Foods’ 3D Bio-Printed Cultivated Meats – Xtalks Life Food Podcast Ep. 78

XTalks

US President Joe Biden recently issued an executive order entitled, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.”

AmerisourceBergen inks €1.3bn PharmaLex buyout to grow biopharma service business

Outsourcing Pharma

AmerisourceBergen has followed through on plans to grow its biopharma services business by striking a â1.28bn ($1.28bn) deal to acquire PharmaLex. Preclinical Research

Sesen Bio and Carisma enter deal to combine businesses

Pharmaceutical Technology

Sesen Bio has signed a definitive merger agreement to combine its business with Carisma Therapeutics and create a clinical-stage biotechnology firm in an all-stock deal. .

Epic launches program to ‘unify’ clinical research with care delivery

Outsourcing Pharma

Epicâs Life Sciences program is released with the aim to connect providers, pharmaceutical companies, and medical device manufacturers to recruit research participants, expand clinical trial access, and to speed up therapy development. Clinical Development

Revamped Novartis highlights top R&D programmes at management update

Pharma Phorum

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for growth at a meeting with investors and analysts, which it says will be driven mainly by five drugs.

Solving CAR-T’s viral vector problem: Cellares and iVexSol team up to streamline manufacturing

BioPharma Reporter

San Francisco based Cellares is partnering with Lexington, Massachusetts headquartered iVexSol to accelerate and improve the quality of viral vector manufacturing and transduction. Bio Developments